|
US7048906B2
(en)
|
1995-05-17 |
2006-05-23 |
Cedars-Sinai Medical Center |
Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
|
|
DE122007000044I2
(de)
*
|
1997-01-07 |
2011-05-05 |
Amylin Pharmaceuticals Inc |
Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
|
|
ES2253353T3
(es)
*
|
2000-03-08 |
2006-06-01 |
Novo Nordisk A/S |
Reduccion del colesterol serico.
|
|
US20030040469A1
(en)
*
|
2000-03-08 |
2003-02-27 |
Knudsen Liselotte Bjerre |
Lowering serum lipids
|
|
ATE408414T1
(de)
|
2001-07-31 |
2008-10-15 |
Us Gov Health & Human Serv |
Glp 1 exendin 4 peptidanaloga und deren verwendungen
|
|
CN100350968C
(zh)
|
2001-09-24 |
2007-11-28 |
皇家创新有限公司 |
饮食行为的改进
|
|
EP1474163A2
(en)
|
2002-01-10 |
2004-11-10 |
Imperial College Innovations Limited |
Modification of feeding behavior
|
|
US8603969B2
(en)
|
2004-02-11 |
2013-12-10 |
Amylin Pharmaceuticals, Llc |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
|
DE102004043153B4
(de)
*
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
|
KR20070115947A
(ko)
|
2005-02-11 |
2007-12-06 |
아밀린 파마슈티칼스, 인크. |
선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
WO2007022123A2
(en)
*
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
|
US20060190425A1
(en)
*
|
2005-02-24 |
2006-08-24 |
Yuan-Chi Chang |
Method for merging multiple ranked lists with bounded memory
|
|
CN101193626A
(zh)
*
|
2005-03-11 |
2008-06-04 |
益德威士医药股份有限公司 |
奥曲肽的受控释放制剂
|
|
US7759312B2
(en)
*
|
2005-03-11 |
2010-07-20 |
Endo Pharmaceuticals Solutions Inc. |
Delivery of dry formulations of octreotide
|
|
CN101258163B
(zh)
|
2005-06-30 |
2013-08-21 |
益普生制药股份有限公司 |
Glp-1药物组合物
|
|
MX2008002028A
(es)
*
|
2005-08-11 |
2008-03-27 |
Amylin Pharmaceuticals Inc |
Polipeptidos hibridos con propiedades de seleccion.
|
|
PL1971362T3
(pl)
|
2005-08-19 |
2015-05-29 |
Amylin Pharmaceuticals Llc |
Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
|
RU2413528C2
(ru)
|
2007-01-18 |
2011-03-10 |
Открытое Акционерное Общество "Валента Фармацевтика" |
Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
|
|
KR100805208B1
(ko)
|
2007-03-27 |
2008-02-21 |
주식회사 펩트론 |
엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
|
|
WO2009033739A2
(en)
*
|
2007-09-11 |
2009-03-19 |
Mondobiotech Laboratories Ag |
Use of a peptide as a therapeutic agent
|
|
KR20100061481A
(ko)
*
|
2007-09-11 |
2010-06-07 |
몬도바이오테크 래보래토리즈 아게 |
치료제로서의 미니가스트린
|
|
WO2009143285A2
(en)
|
2008-05-21 |
2009-11-26 |
Amylin Pharmaceuticals, Inc. |
Exendins to lower cholestrol and triglycerides
|
|
CA2729139C
(en)
|
2008-06-25 |
2016-07-26 |
Endo Pharmaceuticals Solutions Inc. |
Octreotide implant having a release agent
|
|
EP2303226B1
(en)
*
|
2008-06-25 |
2016-03-23 |
Endo Pharmaceuticals Solutions Inc. |
Sustained delivery of exenatide and other polypeptides
|
|
EP2216042A1
(en)
|
2009-02-09 |
2010-08-11 |
Ipsen Pharma S.A.S. |
GLP-1 analogues pharmaceutical compositions
|
|
EP2435061A4
(en)
|
2009-05-28 |
2013-03-27 |
Amylin Pharmaceuticals Inc |
DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
|
|
JP2013530993A
(ja)
|
2010-07-02 |
2013-08-01 |
アンジオケム インコーポレーテッド |
治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用
|
|
US9161953B2
(en)
|
2010-12-22 |
2015-10-20 |
Amylin Pharmaceuticals, Llc |
GLP-1 receptor agonists for islet cell transplantation
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
AU2013366692B2
(en)
|
2012-12-21 |
2017-11-23 |
Sanofi |
Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
EP3080152A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
RU2573933C1
(ru)
|
2014-08-21 |
2016-01-27 |
Дафот Энтерпрайсис Лимитед |
Пептид для лечения сахарного диабета 2-го типа и его осложнений
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
|
|
UA127495C2
(uk)
|
2015-12-23 |
2023-09-13 |
Амджен Інк. |
Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
|
|
WO2018071528A1
(en)
*
|
2016-10-11 |
2018-04-19 |
University Of Georgia Research Foundation, Inc. |
Proteins and method for treating obesity and associated comorbidities
|
|
US11285180B2
(en)
|
2016-12-06 |
2022-03-29 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
|
|
BR112019012693A2
(pt)
*
|
2016-12-22 |
2019-11-19 |
Sanofi |
combinações de composto de fgf21/agonista do glp-1r com razão de atividade otimizada
|
|
IL313587A
(en)
|
2017-01-17 |
2024-08-01 |
Amgen Inc |
Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
|
|
EA201992502A1
(ru)
|
2017-06-20 |
2020-04-22 |
Эмджен Инк. |
Способ лечения или уменьшения интенсивности метаболических нарушений с применением белков, связывающих рецептор гастроингибиторного пептида (gipr), в комбинации с агонистами glp-1
|
|
EP3642238A1
(en)
|
2017-06-21 |
2020-04-29 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
|
|
WO2020185533A1
(en)
|
2019-03-08 |
2020-09-17 |
Amgen Inc. |
Growth differentiation factor 15 combination therapy
|
|
WO2024123812A1
(en)
|
2022-12-05 |
2024-06-13 |
Shattuck Labs, Inc. |
Fusion proteins for the treatment of cardiometabolic diseases
|